We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$395M
AUM Growth
-$219M
Cap. Flow
-$156M
Cap. Flow %
-39.58%
Top 10 Hldgs %
44.14%
Holding
133
New
27
Increased
24
Reduced
29
Closed
30

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.2M
2
CELG
Celgene Corp
CELG
+$7.8M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.42M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$5.26M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.79M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$16.1M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
BIIB icon
Biogen
BIIB
+$15.7M
4
PFE icon
Pfizer
PFE
+$14.4M
5
AMGN icon
Amgen
AMGN
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 60.69%
2 Technology 5.44%
3 Communication Services 2.79%
4 Industrials 1.83%
5 Consumer Discretionary 1.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$32.6M 8.24%
550,000
-1,050,000
-66% -$63.1M
MRK icon
2
Merck
MRK
$322B
$26.5M 6.71%
471,600
+157,200
+50% +$9.2M
CELG
3
DELISTED
Celgene Corp
CELG
$20.8M 5.27%
180,000
+70,000
+64% +$7.8M
TEVA icon
4
Teva Pharmaceuticals
TEVA
$40.8B
$18.9M 4.79%
522,000
+120,000
+30% +$4.79M
OEF icon
5
PUT
iShares S&P 100 ETF
OEF
$20.1B
$16.2M 4.09%
112,000
-108,500
-49% -$10.5M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$13.8M 3.5%
113,000
+43,000
+61% +$5.26M
OEF icon
7
CALL
iShares S&P 100 ETF
OEF
$20.1B
$13.5M 3.41%
+100,000
New +$9.7M
CLCD
8
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$13M 3.3%
358,000
-42,000
-11% -$1.49M
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.57B
$10.9M 2.76%
398,047
+135,000
+51% +$5.42M
ITRN icon
10
Ituran Location and Control
ITRN
$1.09B
$8.13M 2.06%
306,633
-150,035
-33% -$3.89M
ARRY
11
DELISTED
Array Biopharma Inc
ARRY
$7.91M 2%
900,000
– –
TEVA icon
12
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$7.79M 1.97%
+215,000
New +$8.58M
AKAO
13
DELISTED
Achaogen Inc
AKAO
$6.7M 1.7%
514,342
-785,971
-60% -$5.39M
ASND icon
14
Ascendis Pharma A/S
ASND
$16B
$6.61M 1.67%
326,622
+63,122
+24% +$1.26M
SHPG
15
DELISTED
Shire pic
SHPG
$5.54M 1.4%
32,500
+25,000
+333% +$4.43M
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.85M 1.23%
300,000
-235,000
-44% -$4.26M
CHTR icon
17
Charter Communications
CHTR
$17.3B
$4.65M 1.18%
16,165
– –
RNAC icon
18
Cartesian Therapeutics
RNAC
$229M
$4.61M 1.17%
8,951
-537
-6% -$314K
SAGE
19
DELISTED
Sage Therapeutics
SAGE
$4.59M 1.16%
90,000
-69,500
-44% -$3.28M
CRVS icon
20
Corvus Pharmaceuticals
CRVS
$1.12B
$4.58M 1.16%
320,229
-4,824
-1% -$73.4K
ADMS
21
DELISTED
Adamas Pharmaceuticals
ADMS
$4.56M 1.16%
270,000
– –
GOOGL icon
22
Alphabet (Google) Class A
GOOGL
$4.36T
$4.55M 1.15%
114,960
+18,600
+19% +$744K
CBIO
23
Crescent Biopharma
CBIO
$535M
$4.55M 1.15%
7,458
+277
+4% +$173K
EIGR
24
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.49M 1.14%
12,843
+391
+3% +$143K
V icon
25
Visa
V
$684B
$4.05M 1.03%
51,951
+9,160
+21% +$736K
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sphera Funds Management held 133 positions worth $395M, down 36% from $614M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sphera Funds Management withdrew a net $156M in Q4 2016, closing 30 positions and reducing 29 holdings. Its most notable exit was Allergan plc, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in BioMarin Pharmaceuticals worth $3.73M.

  • Sphera Funds Management's largest Q4 2016 buy was BioMarin Pharmaceuticals: 45,000 shares worth $3.73M.
  • Sphera Funds Management added most to Merck in Q4 2016, an estimated $9.2M increase.
  • Sphera Funds Management's biggest Q4 2016 reduction was Achaogen Inc, cutting an estimated $5.39M.
  • Sphera Funds Management fully exited Allergan plc in Q4 2016, selling an estimated $16.1M.
  • Sphera Funds Management's ten largest holdings make up 44% of its $395M portfolio in Q4 2016.
  • Sphera Funds Management opened 27 new positions and closed 30 in Q4 2016.
  • Sphera Funds Management's portfolio value fell 36% quarter-over-quarter to $395M.

Based on Sphera Funds Management's 13F filing for Q4 2016, filed 13 Feb 2017.